NCT02645149 2026-02-27
Match Mel
Melanoma Institute Australia
Phase 2 Completed
Clinical Trials
10 trialsNCT04594187 2026-02-17
MelPORT
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06146920 2025-11-18
Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation
Massachusetts General Hospital
Phase NA Active not recruiting
NCT06624644 2025-09-10
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
Linnaeus Therapeutics, Inc.
Phase 2/3 Recruiting
NCT05478876 2024-08-21
CYCLE
CNAO National Center of Oncological Hadrontherapy
Phase NA Recruiting
NCT04242329 2024-01-26
SUMMIST
Vastra Gotaland Region
Phase 2 Withdrawn
NCT01176474 2023-07-19
Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02054520 2023-04-18
Immunotherapy Study for Patients With Stage IV Melanoma
Lumos Pharma
Phase 2 Terminated
NCT01176461 2023-01-18
Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT00101166 2018-02-28
Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed